In 28 chapters, Global Epidemiology of Cancer provides a basic overview of the most commonly occurring cancers, their worldwide incidence, and mortality. Designed for the health sciences, particularly those in epidemiology, public health, and medicine, this comprehensive resource is ideal as a primary text for an overview course or seminar on Cancer or Cancer epidemiology. Key Features: - Backed with research and draws upon worldwide information to address the global landscape of cancer. - Offers clear, concise descriptions of each specific type of oncologic disease as well as its epidemiology, etiology, risk factors and preventive factors - Includes a wealth of information on the pathogenesis of the disease as we currently understand it at the molecular level.

This atlas illustrates the latest available data on the cancer epidemic, showing causes, stages of development, and prevalence rates of different types of cancers by gender, income group, and region. It also examines the cost of the disease, both in terms of health care and commercial interests, and the steps being taken to curb the epidemic, from research and screening to cancer management programs and health education.

Cancer is low or absent on the health agendas of low- and middle-income countries (LMCs) despite the fact that more people die from cancer in these countries than from AIDS and malaria combined. International health organizations, bilateral aid agencies, and major foundations—which are instrumental in setting health priorities—also have largely ignored cancer in these countries. This book identifies feasible, affordable steps for LMCs and their international partners to begin to reduce the cancer burden for current and future generations. Stemming the growth of cigarette smoking tops the list to prevent cancer and all the other major chronic diseases. Other priorities include infant vaccination against the hepatitis B virus to prevent liver cancers and vaccination to prevent cervical cancer. Developing and increasing capacity for cancer screening and treatment of highly curable cancers (including most childhood malignancies) can be accomplished using "resource-level appropriateness" as a guide. And there are ways to make inexpensive oral morphine available to ease the pain of the many who will still die from cancer.

A basic textbook addressed to medical and public health students, clinicians, health professionals, and all others seeking to understand the principles and methods used in cancer epidemiology. Written by a prominent epidemiologist and experienced teacher at the London School of Hygiene and Tropical Medicine, the text aims to help readers become competent in the use of basic epidemiological tools and capable of exercising critical judgment when assessing results reported by others. Throughout the text, a lively writing style and numerous illustrative examples, often using real research data, facilitate an easy understanding of basic concepts and methods. Information ranges from an entertaining account of the origins of epidemiology, through advice on how to overcome some of the limitations of survival analysis, to a checklist of questions to ask when considering sources of bias. Although statistical concepts and formulae are presented, the emphasis is consistently on the interpretation of the data rather than on the actual calculations. The text has 18 chapters. The first six introduce the basic principles of epidemiology and statistics. Chapters 7-13 deal in more depth with each of the study designs and interpretation of their findings. Two chapters, concerned with the problems of confounding and study size, cover more complex statistical concepts and are included for advanced study. A chapter on methodological issues in cancer prevention gives examples of epidemiology's contribution to primary prevention, screening and other activities for early detection, and tertiary prevention. The concluding chapters review the role of cancer registries and discuss practical considerations that should be taken into account in the design, planning, and conduct of any type of epidemiological research.

Breast cancer remains a disease of considerable public health importance worldwide, with over 800,000 new cases diagnosed globally each year. Considerable energy is currently being spent by researchers to further our understanding of this complex disease, however, keeping up with all of the new data is a real challenge given the sheer volume of information that becomes available on a daily basis. The purpose of this book would be to provide a comprehensive review of breast cancer epidemiology, covering the topics of disease burden, etiology, risk factors, prevention, early detection/screening, treatment, and outcomes. The book would be a single comprehensive source of the most recent information on breast cancer epidemiology, and it would serve as a valuable resource for breast cancer researchers across disciplines regardless of what stage of their career they are in. To the knowledge of the editor, no such resource is currently available.

This report presents the latest national survival and prevalence statistics for cancers in Australia from 1982 to 2010. Survival from cancer is a key indicator of cancer prognosis, control and treatment. It refers to the probability of being alive for a given amount of time after diagnosis and reflects the severity of a cancer diagnosis.

This superb text gives a concise, systematic account of what is currently known about the epidemiology and primary prevention for most forms of human cancer. Part 1 provides an introduction to basic concepts in epidemiology, a description of the global burden of cancer, definitions and characterizations of the various measures used, and approaches used to reveal genetic determinants of cancer risk and integrate biologic markers in the epidemiogic research process. Part 2 contains chapters of uniform structure on over 20 types of cancer, providing clinical and pathological outlines, descriptive epidemiology, and a comprehensive account of risk factors and their etiological importance. Specific sections address somatic and germ cell mutations that play a role in the occurrence of particular forms of cancer.

Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.

In the late 1980s, the National Cancer Institute initiated an investigation of cancer risks in populations near 52 commercial nuclear power plants and 10 Department of Energy nuclear facilities (including research and nuclear weapons production facilities and one reprocessing plant) in the United States. The results of the NCI investigation were used a primary resource for communicating with the public about the cancer risks near the nuclear facilities. However, this study is now over 20 years old. The U.S. Nuclear Regulatory Commission requested that the National Academy of Sciences provide an updated assessment of cancer risks in populations near USNRC-licensed nuclear facilities that utilize or process uranium for the production of electricity. Analysis of Cancer Risks in Populations near Nuclear Facilities: Phase 1 focuses on identifying scientifically sound approaches for carrying out an assessment of cancer risks associated with living near a nuclear facility, judgments about the strengths and weaknesses of various statistical power, ability to assess potential confounding factors, possible biases, and required effort. The results from this Phase 1 study will be used to inform the design of cancer risk assessment, which will be carried out in Phase 2. This report is beneficial for the general public, communities near nuclear facilities, stakeholders, healthcare providers, policy makers, state and local officials, community leaders, and the media.